anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In aquatic ectotherms, temperature plays a pivotal role in biological processes and the prevalence of viral diseases; however, the molecular mechanisms underlying these effects are not fully elucidated. In this study, we investigate the impact of elevated temperatures (32°C) on the immune response against white spot syndrome virus (WSSV) in shrimp (Litopenaeus vannamei). Our findings reveal that higher water temperatures, specifically 32°C, significantly inhibit WSSV replication and pathogenicity, thereby enhancing the survival rates of infected shrimp. Through transcriptome analysis and in vivo experiments, we identified heat shock protein 70 (HSP70) as a key factor in this thermal regulation of immunity. Shrimp maintained at 32°C, with silenced HSP70 expression, exhibited increased viral loads and reduced survival, underscoring the crucial protective role of HSP70 against WSSV at elevated temperatures. Our results further uncover the HSP70-Toll4-Dorsal-antimicrobial peptide (AMP) pathway as a key mediator of WSSV resistance at elevated temperatures. This pathway involves the interaction of HSP70 with the Toll4 receptor, resulting in the phosphorylation of Dorsal and the consequent modulation of expression of AMPs such as the anti-LPS factor (ALF) and lysozyme (LYZ) families. Taken together, these findings advance our understanding of temperature's role in disease dynamics in aquatic ectotherms, especially the unexpected roles of HSP70 in shrimp in facilitating the innate immune system's response to thermal stress, and suggest new approaches to managing WSSV in shrimp farming, such as environmental temperature control or HSP70 induction.
This is a voluntary 8-week-long, non-medical intervention study for patients with hidradenitis suppurativa (HS). This study will enroll participants in an 8-week-long Mindfulness-Based Stress Reduction course and observed for any changes in validated measures of quality of life. Quality of life scores will be evaluated via multiple surveys including the Dermatology Quality of Life index, HS Quality of Life index, GAD7, and PHQ9. Surveys will be collected Week 1 of 8 week MBSR course intervention; Week 4; End of MBSR Course at week 8; and Week 12. The first goal is to investigate the effectiveness of the addition of mindfulness-based stress reduction (MBSR) intervention to conventional medical treatment on improving mental health in HS participants. The second goal is to assess participant preference for MBSR intervention.
IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
Starts 2 weeks after ending standard cardiac rehabilitation (CR) and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
Participants received 155 U of onabotulinumtoxinA (BOTOX®) approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
PROBLEM TO BE SOLVED: To obtain the orally administrable medicine capable of effectively improving the blood lipoprotein lipase activity-lowering disease without being accompanied by side effects by including spherical activated carbon as an active ingredient. SOLUTION: This medicine contains spherical activated carbon having a diameter of 0.05-2 mm and excellent in adsorbability as an active ingredient. The spherical activated carbon preferably has a specific surface area of 500-2,000 m<2> /g, a pore diameter of 100-75,000 Å and a porosity of 0.01-1 ml/g. The medicine is useful as a gout- improving medicine and an epidemic-improving medicine in addition to the medicine for improving the blood lipoprotein lipase activity-lowering disease. The medicine is orally administered as a daily dose of 0.2-30 g as the spherical activated carbon as such or as an activated carbon preparation for man.  The spherical activated carbon can be produced by carbonizing an arbitrary activated carbon raw material e.g. saw dust, various kind of pitches such as coal or petroleum pitch or organic synthetic polymers, and subsequently activating the carbonization product by a method such as a steam-activating method, a chemical activating method, an air-activating method or a carbon dioxide-activating method.
PURPOSE:To provide a skin-beautifying agent and skin cosmetic containing phosphoramidon having peptidase inhibiting action as an essential component, having beautifying effect on the skin after ultraviolet irradiation and effective for preventing and treating spots and freckles caused by sunburn, etc. CONSTITUTION:The objective skin-beautifying agent and skin cosmetic are composed of phosphoramidon expressed by formula. Phosphoramidon of formula exhibits excellent effect for preventing and ameliorating pigmentation and has high safety. The skin cosmetic can be used in the form of cream, milky lotion, face lotion, foundation, pack, lotion, gel, solution, stick, etc. Commercially available phosphoramidon can be used for the purpose and the content of phosphoramidon in the skin cosmetic is preferably 0.0001-5%. The skin cosmetic may be properly incorporated, in addition to the phosphoramidon used as an essential component, with lubricant, humectant, thickener, antiseptic, emulsifier, pigment, powder, pH-modifier, drug active component, ultraviolet absorbent, antioxidant, flavor, etc.
PURPOSE:A cholagogue that contains, as a major active ingredient, a fraction soluble in an organic solvent, obtained by extraction of herb medicine in Zingiberaceae with an organic solvent, thus showing high durative effect. CONSTITUTION:A herb medicine in Zingiberaceae such as ginger or dried ginger is extracted with an organic solvent such as ethyl acetate or ethyl ether and the fraction soluble in the organic solvent is used as a major component. The fraction is obtained by cuttig the herb medicine into rough pieces, decocting with an organic solvent, and filtering. The decocting and filtration are repeated twice, then the extracts are combined, concentrated under reduced pressure at a temperature lower than 50 deg.C. The resultant fraction shows marked improved cholagogue effect compared with sodium deoxycholate as a reference. When the solvent for the extraction is relatively small in polarity such as ethyl acetate, it shows especially high cholagogue effect.
The invention comprises an oral Omega-3-fatty acid-rich oil emulsion composition comprising DHA 50-100 mg/ml, made from all natural and biocompatible ingredients for use in management of treatment of a disorder to overcome the same. The composition may be a thixotropic emulsion in nanometric size range having better absorption, better stability at room temperature and refrigerated one (2-8̊C), either alone or in combination with vitamins, minerals, Generally Regarded As safe (GRAS) natural ingredients. in therapeutically effective amount. The disorders comprise pre-term birth disorder in pregnant women, cognitive disorders in children and cardiovascular disorders. The said emulsion is made by adding an oil phase comprising a natural emulsifier to an aqueous phase comprising a gum. Vitamin E TPGS, a preservative and a high intensity sweetener; under mechanical stirring. This invention also embodies a High Performance Liquid Chromatography (HPLC) method for assay of omega-3 fatty acids.
PURPOSE:To provide a copolymer useful as an in-vivo decomposable polymer in the fields of medicine and medical treatment, by subjecting a malide benzyl ester and an L-lactide to a ring-opening polymn. reaction and debenzylating the product. CONSTITUTION:A malide benzyl ester of formula I, which is a cyclic dimer of beta-benzyl-L-malic acid, and an L-lactide of formula II, which is a cyclic dimer of L-lactic acid, are subjected to a ring-opening polymn. reaction in the presence of an organotin catalyst (e.g., tin caprylate) at 150-300 deg.C. The resulting reaction mixture is dissolved in a solvent and treated with acetic anhydride to protect the terminals of the polymer. The polymer is crystallized to obtain a beta-benzyl malate/lactic acid copolymer. The copolymer is catalytically reduced in the presence of a Pd-carbon catalyst or a platinum black catalyst to debenzylate the copolymer, thus obtaining an alpha-malic acid/lactic acid copolymer having an alpha-malic acid fraction of 5-25% by mol. and a mol.wt. of not lower than 1,000.
Instruct patients and/or caregivers to read the “Instructions for Use” carefully for complete directions on how to properly dose and administer SYMPAZAN® oral films.

Apply SYMPAZAN® on top of the tongue where it adheres and dissolves.

SYMPAZAN® oral film can be taken with or without food [see Clinical Pharmacology (12.3)]. Do not administer with liquids. As the film dissolves, saliva should be swallowed in a normal manner, but the patient should refrain from chewing, spitting or talking.

Only one oral film should be taken at a time; if a second film is needed to complete the dosage, it should not be taken until the first film has completely dissolved.
In randomized controlled trials of treatment-naive patients, clinical lipoatrophy developed in a higher proportion of patients treated with stavudine compared to other nucleosides (tenofovir or abacavir). Dual energy x-ray absorptiometry (DEXA) scans demonstrated overall limb fat loss in stavudine-treated patients compared to limb fat gain or no gain in patients treated with other nucleosides (abacavir, tenofovir, or zidovudine). The incidence and severity of lipoatrophy are cumulative over time with stavudine-containing regimens. In clinical trials, switching from stavudine to other nucleosides (tenofovir or abacavir) resulted in increases in limb fat with modest to no improvements in clinical lipoatrophy. 

Patients receiving stavudine should be monitored for symptoms or signs of lipoatrophy and questioned about body changes related to lipoatrophy. Given the potential risks of using stavudine including lipoatrophy, a benefit-risk assessment for each patient should be made and an alternative antiretroviral should be considered.
IMPORTANCE: Obesity is a disease with a large socioeconomic burden. Endoscopic sleeve gastroplasty (ESG) is a minimally invasive endoscopic bariatric procedure with wide global adoption. More recently, new weight-loss medications, such as glucagon-like peptide-1 receptor agonists (eg, semaglutide), have attracted increased attention due to their efficacy. However, their cost-effectiveness over an extended period compared with ESG is a critical gap that needs to be better explored for informed health care decision-making.
OBJECTIVE: To assess the cost-effectiveness of semaglutide compared with ESG over 5 years for individuals with class II obesity.
DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation study, conducted from September 1, 2022, to May 31, 2023, used a Markov cohort model to compare ESG and semaglutide, with a no-treatment baseline strategy. The study comprised adult patients in the US health care system with class II obesity (body mass index [BMI] of 35-39.9). The base case was a 45-year-old patient with class II obesity (BMI of 37). Patients undergoing ESG were subjected to risks of perioperative mortality and adverse events with resultant costs and decrement in quality of life.
INTERVENTIONS: Strategies included treatment with semaglutide and ESG.
MAIN OUTCOMES AND MEASURES: Costs (2022 US dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) with a willingness-to-pay threshold of $100 000/QALY. A 5-year time horizon with a cycle length of 1 month with a 3% discount rate was used. Probabilities, costs, and quality-of-life estimates of the model were derived from published literature. One-way, 2-way, and probabilistic sensitivity analyses were also performed.
RESULTS: The model found that ESG was more cost-effective than semaglutide over a 5-year time horizon, with an ICER of -$595 532/QALY. Endoscopic sleeve gastroplasty added 0.06 QALYs and reduced total cost by $33 583 relative to semaglutide. The results remained robust on 1-way and probabilistic sensitivity analyses. Endoscopic sleeve gastroplasty sustained greater weight loss over 5 years vs semaglutide (BMI of 31.7 vs 33.0). To achieve nondominance, the annual price of semaglutide, currently $13 618, would need to be $3591.
CONCLUSIONS AND RELEVANCE: This study suggests that ESG is cost saving compared with semaglutide in the treatment of class II obesity. On price threshold analyses, a 3-fold decrease in the price of semaglutide is needed to achieve nondominance.
The invention discloses a gene editing system for constructing a pig nuclear transplantation donor cell of a PAH (phenylalanine ammonia-lyase) gene mutant model and application thereof. The present invention provides a polypeptide comprising SEQ ID NO:16, PAH-gRNA1, SEQ ID NO:17, PAH-gRNA4 and NCN protein. The invention also provides a method for preparing the recombinant cell: co-transfecting the PAH-gRNA1, the PAH-gRNA4 and the NCN protein to a pig cell to obtain a recombinant cell. The recombinant cell is a recombinant cell with mutation of PAH gene. The application of the kit is as follows: preparing a recombinant cell; preparing a phenylketonuria model pig; preparing a phenylketonuria cell model or a phenylketonuria tissue model or a phenylketonuria organ model. The invention has great application value for researching and developing the phenylketonuria medicament and disclosing the pathogenesis of the phenylketonuria medicament.
Following the advent of direct-acting antivirals (DAAs), the treatment of hepatitis C virus (HCV) infection is now rarely challenging. However, data are still limited concerning DAA use in patients affected by glucose-6-phosphate dehydrogenase deficiency (G6PDd). Based on these considerations, the goal of this study was to evaluate the effectiveness and safety of DAAs in this subpopulation. A retrospective multicenter observational study (2015-2023) was conducted on all 2754 consecutive HCV-positive patients treated with first- and second-generation all-oral DAAs, and with a G6PDd diagnosis confirmed by quantitative testing (n = 38). At the treating clinician's discretion, an enhanced clinical and laboratory follow-up was performed, generally on a monthly basis both during treatment and up to six months after the end of it. Concerning hematochemical parameters, no significant differences were found between any considered time point. In all cases, no treatment-related adverse events were reported, and virologic response rates were as expected without G6PDd. In conclusion, in a large experience which, to the best of our knowledge, is unprecedented in the literature, the treatment of HCV hepatitis with nearly all available DAAs in patients with G6PDd as a comorbidity-a common occurrence in countries such as Italy-proved to be highly effective and safe.
Stage 1:Patient identification form, follow-up form, State Continuity Anxiety Scale, Richard Campbell Sleep Scale were filled in.Stage2: 2-3 drops of distilled water dripped onto the prepared pillow bags at 21:00 on the second and third days of the surgery by inhalation. They were asked to breathe and after 20 minutes, these sacs were taken and placed 10 cm away from the patient.Stage 3:These sacs were taken from the bedside of the patient at 08:00 in the morning and the patient follow-up form, State-Trait Anxiety Scale, Richards Campbell Sleep Scale were filled again.
This randomized controlled, double-blinded crossover study aims to investigate the antithrombotic activities of a novel yoghurt drink in healthy adult volunteers. It is anticipated that the novel drink containing beneficial polar lipids will reduce platelet aggregation in participants and consequently decrease the onset of cardiovascular disease.

In Phase I, the subjects will provide blood samples after overnight fasting and then take either a yoghurt drink (YD) or placebo (that does not contain polar lipids) daily for 4 weeks. Following this period, they will again provide blood samples. Then, after a 2-week washout period in which the subjects do not take any yoghurt or placebo drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis.
On arrival at the recruiting hospital, eligible and consenting STEMI patients randomly allocated to the experimental arm would be administered an intravenous N-Acetylcysteine bolus of 1200 mg over 0.5 hours (in 5% Dextrose) followed by 600mg/hour for the remaining 47.5 hours (in 5% dextrose). A total N-acetylcysteine dose of 29.7 grams is administered over 48 hours.
The invention discloses spleen-invigorating and food-retention removing nutritional powder for children. The spleen-invigorating and food-retention removing nutritional powder for children is developed with great concentration according to a physiological characteristic of 'superabundance often exists in liver and hypoactivity often exists in spleen' of infants and young children and the characteristic that most of infants and young children are inadequate in natural endowment and need nutrition supplement, and consists of twenty traditional Chinese medicines including rice, radix astragali and the like. Codonopsis pilosula and white atractylodes rhizome invigorate middle energizer, benefit vital energy and the spleen and eliminate dampness. Tuckahoe invigorates the spleen, alleviates water retention, checks diarrhea and has the effect of decoction of four noble drugs. The radix astragali and Chinese angelica nourish the vitality, promote blood and have the effect of hematogenesis soup. Hawthorn and cutin internal walls promote digestion and remove food retention and promote the vital energy circulation. Cardamom kernels regulate the vital energy, stimulate appetite, check diarrhea and control nocturnal emission. Hyacinth beans invigorate the spleen and the vital energy, clear heat and promote diuresis. Chinese yam strengthens spleen and kidney. Rehmannia rhizome clears deficient heat, balances yin and yang and enables the fruits of Rangoon creeper and parasites to be removed. The rice mainly accounts for 80 % of total amount. The Nutritional powder for invigorating the spleen and removing the food retention of the children strengthens vital energy and produces blood, invigorates the middle energizer, stimulates the appetite, invigorates spleen to promote digestion, nourishes kidney, strengthens bones, gets rid of intestinal parasites, reduces the food retention, promotes growth and development, enables foreheads of the infants and the young children to jointed quickly, enables hair to be grow early, enables the infants and the young children to speak and walk early, enables intestines and stomach to be good, and enables the infants and the young children to grow tall and fat and have good health.
In the dynamic process of metastasis, circulating tumor cells (CTCs) emanate from the primary solid tumor and subsequently acquire the capacity to disengage from the basement membrane, facilitating their infiltration into the vascular system via the interstitial tissue. Given the pivotal role of CTCs in the intricate hematogenous metastasis, they have emerged as an essential resource for a deeper comprehension of cancer metastasis while also serving as a cornerstone for the development of new indicators for early cancer screening and new therapeutic targets. In the epoch of precision medicine, as CTC enrichment and separation technologies continually advance and reach full fruition, the domain of CTC research has transcended the mere straightforward detection and quantification. The rapid advancement of CTC analysis platforms has presented a compelling opportunity for in-depth exploration of CTCs within the bloodstream. Here, we provide an overview of the current status and research significance of multi-omics studies on CTCs, including genomics, transcriptomics, proteomics, and metabolomics. These studies have contributed to uncovering the unique heterogeneity of CTCs and identifying potential metastatic targets as well as specific recognition sites. We also review the impact of various states of CTCs in the bloodstream on their metastatic potential, such as clustered CTCs, interactions with other blood components, and the phenotypic states of CTCs after undergoing epithelial-mesenchymal transition (EMT). Within this context, we also discuss the therapeutic implications and potential of CTCs.
The invention discloses a many-year-standing vegetable meat ball and aims at providing a making method of a meatball which is rich in nutrient, tender, smooth, tasty, refreshing and delicious in taste. The meatball is prepared from, by weight, 75-85 parts of many-year-standing vegetables, 4-6 parts of ham, 10-15 parts of fresh roots of kudzu vine, 4-8 parts of fragrant-flowered garlic, 1-1.5 parts of rapeseed oil, 0.2-0.8 part of ginger, 0.5-1 part of garlic, 0.5-1 part of ground pepper, 1-3 parts of cooling wine and 1.5-3 parts of tea soup. The tea soup is made by boiling one part of tea and 20 parts of water. The making method includes the steps that the fresh roots of kudzu vine are steamed and smashed into paste; the many-year-standing vegetables, the ham, the fragrant-flowered garlic, the ginger, the rapeseed oil and the ground pepper which are minced are added into the paste of the roots of kudzu vine, mixtures are stirred into dough-shaped mixed materials, and dough-shaped mixed materials are extruded into meatballs. The meatball is delicious in taste, unique in taste and oily but not greasy and has strong local features. The making method of a dish is provided.
Amyotrophic lateral sclerosis is a neurodegenerative disorder. Despite extensive studies, it remains challenging to treat ALS. Recent ALS studies have shown dysbiosis (e.g., loss of microbial diversity and beneficial function in the gut microbiota) is correlated with intestinal inflammation and change of intestinal integrity in ALS. The novel concepts and the roles of microbiome and microbial metabolites through the gut-microbiome-neuron axis in ALS pathogenesis have been slowly recognized by the neurology research field. Here, we will discuss the recent progress of microbiome, including bacteria, fungi, and viruses, in the ALS research. We will discuss our understanding of microbial metabolites in ALS. Micronutrition refers to the intake of essential vitamins, minerals, and other micronutrients. We will summarize the literation related to micronutrition and ALS. Furthermore, we will consider the mutual interactions of microbiome and micronutrition in the ALS progression and treatment. We further propose that the mechanistic and translational studies that shift from suspension of disbelief to cogent ingenuity, and from bench study to bed-side application, should allow new strategies of diagnosis and treatment for ALS.
The chest compression scenario, where continuous chest compression was applied using chest compression system LUCAS-2 (Physio-Control, Redmond, WA, USA). Chest compression was provided at a rate of 100 min-1 to a depth of 5-6 cm during all intubation procedures.